Solid Lipid Nanoparticles Loaded with Nisin (SLN-Nisin) are More Effective Than Free Nisin as Antimicrobial, Antibiofilm, and Anticancer Agents

Radaic, Allan; Malone, Erin; Kamarajan, Pachiyappan; Kapila, Yvonne L.

doi:10.1166/jbn.2022.3314

Cited by 15 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral cancer (HSC-3) cell line was maintained as previously described [ 17 , 57 , 58 ]. Briefly, cells were grown in DMEM medium supplemented with 10% FBS and 1% penicillin and streptomycin under a humid atmosphere at 37 °C and 5% CO 2 .…”

Section: Methodsmentioning

confidence: 99%

Specific Oral Microbial Differences in Proteobacteria and Bacteroidetes Are Associated with Distinct Sites When Moving from Healthy Mucosa to Oral Dysplasia—A Microbiome and Gene Profiling Study and Focused Review

Radaic,

Shamir,

Jones

et al. 2023

Microorganisms

Self Cite

View full text Add to dashboard Cite

Oral potentially malignant disorders (OPMDs) are a group of conditions that carry a risk of oral squamous cell carcinoma (OSCC) development. Recent studies indicate that periodontal disease-associated pathogenic bacteria may play a role in the transition from healthy mucosa to dysplasia and to OSCC. Yet, the microbial signatures associated with the transition from healthy mucosa to dysplasia have not been established. To characterize oral microbial signatures at these different sites, we performed a 16S sequencing analysis of both oral swab and formalin-fixed, paraffin-embedded tissue (FFPE) samples. We collected oral swabs from healthy mucosa (from healthy patients), histologically normal mucosa adjacent to dysplasia, and low-grade oral dysplasia. Additionally, FFPE samples from histologically normal mucosa adjacent to OSCC, plus low grade and high-grade oral dysplasia samples were also collected. The collected data demonstrate significant differences in the alpha and beta microbial diversities of different sites in oral mucosa, dysplasia, and OSCC, as well as increased dissimilarities within these sites. We found that the Proteobacteria phyla abundance increased, concurrent with a progressive decrease in the Firmicutes phyla abundance, as well as altered levels of Enterococcus cecorum, Fusobacterium periodonticum, Prevotella melaninogenica, and Fusobacterium canifelinum when moving from healthy to diseased sites. Moreover, the swab sample analysis indicates that the oral microbiome may be altered in areas that are histologically normal, including in mucosa adjacent to dysplasia. Furthermore, trends in specific microbiome changes in oral swab samples preceded those in the tissues, signifying early detection opportunities for clinical diagnosis. In addition, we evaluated the gene expression profile of OSCC cells (HSC-3) infected with either P. gingivalis, T. denticola, F. nucelatum, or S. sanguinis and found that the three periodontopathogens enrich genetic processes related to cancer progression, including skin keratinization/cornification, while the commensal enriched processes related to RNA processing and adhesion. Finally, we reviewed the dysplasia microbiome literature and found a significant decrease in commensal bacteria, such as the Streptococci genus, and a simultaneous increase in pathogenic bacteria, mainly Bacteroidetes phyla and Fusobacterium genus. These findings suggest that features of the oral microbiome can serve as novel biomarkers for dysplasia and OSCC disease progression.

show abstract

Section: Methodsmentioning

confidence: 99%

Specific Oral Microbial Differences in Proteobacteria and Bacteroidetes Are Associated with Distinct Sites When Moving from Healthy Mucosa to Oral Dysplasia—A Microbiome and Gene Profiling Study and Focused Review

Radaic,

Shamir,

Jones

et al. 2023

Microorganisms

Self Cite

View full text Add to dashboard Cite

show abstract

“…172 In a recent study by Radaic and colleagues (2022), nisinloaded SLN (SLN-Nisin) exhibited significant inhibition of Treponema denticola biofilms. 173 Another study evaluated the effectiveness of tobramycin-loaded SLNs against biofilms. 174 The minimum inhibitory concentration (MIC) and minimum biofilm eradication concentration (MBEC) of the nanoencapsulated tobramycin was 1−2 log lower as compared to those of drug-only groups when tested on tobramycinsusceptible isolates.…”

Section: Acsmentioning

confidence: 99%

“…In a recent study by Radaic and colleagues (2022), nisin-loaded SLN (SLN-Nisin) exhibited significant inhibition of Treponema denticola biofilms . Another study evaluated the effectiveness of tobramycin-loaded SLNs against biofilms .…”

Section: Nanotechnological Approaches For Biofilm Controlmentioning

confidence: 99%

Advances in Nanotechnology for Biofilm Inhibition

et al. 2023

View full text Add to dashboard Cite

Biofilm-associated infections have emerged as a significant public health challenge due to their persistent nature and increased resistance to conventional treatment methods. The indiscriminate usage of antibiotics has made us susceptible to a range of multidrug-resistant pathogens. These pathogens show reduced susceptibility to antibiotics and increased intracellular survival. However, current methods for treating biofilms, such as smart materials and targeted drug delivery systems, have not been found effective in preventing biofilm formation. To address this challenge, nanotechnology has provided innovative solutions for preventing and treating biofilm formation by clinically relevant pathogens. Recent advances in nanotechnological strategies, including metallic nanoparticles, functionalized metallic nanoparticles, dendrimers, polymeric nanoparticles, cyclodextrin-based delivery, solid lipid nanoparticles, polymer drug conjugates, and liposomes, may provide valuable technological solutions against infectious diseases. Therefore, it is imperative to conduct a comprehensive review to summarize the recent advancements and limitations of advanced nanotechnologies. The present Review encompasses a summary of infectious agents, the mechanisms that lead to biofilm formation, and the impact of pathogens on human health. In a nutshell, this Review offers a comprehensive survey of the advanced nanotechnological solutions for managing infections. A detailed presentation has been made as to how these strategies may improve biofilm control and prevent infections. The key objective of this Review is to summarize the mechanisms, applications, and prospects of advanced nanotechnologies to provide a better understanding of their impact on biofilm formation by clinically relevant pathogens.

show abstract

“…[4] However, many technical challenges hindered the potential clinical applications of AMPs, including but not limited to, poor physiological stability and uncontrolled bioavailability of those short peptides; [5] therefore, improved AMP delivery strategies are demanded. [6] So far, various drug delivery systems have been evaluated as a carrier for AMPs, including porous materials, [7] polymer-based particles, [8,9] lipid-based particles, [10,11] nanofibers, [12] and hydrogels, [13,14] which encapsulate short peptides either by physical interactions or chemical conjugations. [15] Nevertheless, a successful AMP delivery system should balance the drug release profile and its potency, as well as thorough consideration of the targets, such as internal organs or dermal tissues.…”

Section: Introductionmentioning

confidence: 99%

Dendritic Nanogels Directed Dual‐Encapsulation Topical Delivery System of Antimicrobial Peptides Targeting Skin Infections

Zhang

Håkansson

Fan

et al. 2023

Macromolecular Bioscience

View full text Add to dashboard Cite

Antimicrobial peptides (AMPs) are promising antibacterial agents in the fight against multidrug resistant pathogens. However, their application to skin infections is limited by the absence of a realizable topical delivery strategy. Herein, a hybrid hierarchical delivery system for topical delivery of AMPs is accomplished through the incorporation of AMPs into dendritic nanogels (DNGs) and their subsequent embedding into poloxamer gel. The high level of control over the crosslink density and the number of chosen functionalities makes DNGs ideal capsules with tunable loading capacity for DPK‐060, a human kininogen‐derived AMP. Once embedded into the poloxamer gel, DPK‐060 encapsulated in DNGs displays a slower release rate compared to those entrapped directly in the gels. In vitro EpiDerm Skin Irritation Tests show good biocompatibility, while MIC and time‐kill curves reveal the potency of the peptide toward Staphylococcus aureus. Anti‐infection tests on ex vivo pig skin and in vivo mouse infection models demonstrate that formulations with 0.5% and 1% AMPs significantly inhibit the growth of S. aureus. Similar outcomes are observed for an in vivo mouse surgical site infection model. Importantly, when normalizing the bacteria inhibition to released/free DPK‐060 at the wound site, all formulations display superior efficacy compared to DPK‐060 in solution.

show abstract

Solid Lipid Nanoparticles Loaded with Nisin (SLN-Nisin) are More Effective Than Free Nisin as Antimicrobial, Antibiofilm, and Anticancer Agents

Cited by 15 publications

References 35 publications

Specific Oral Microbial Differences in Proteobacteria and Bacteroidetes Are Associated with Distinct Sites When Moving from Healthy Mucosa to Oral Dysplasia—A Microbiome and Gene Profiling Study and Focused Review

Specific Oral Microbial Differences in Proteobacteria and Bacteroidetes Are Associated with Distinct Sites When Moving from Healthy Mucosa to Oral Dysplasia—A Microbiome and Gene Profiling Study and Focused Review

Advances in Nanotechnology for Biofilm Inhibition

Dendritic Nanogels Directed Dual‐Encapsulation Topical Delivery System of Antimicrobial Peptides Targeting Skin Infections

Contact Info

Product

Resources

About